Trait: QRS duration

Experimental Factor Ontology (EFO) Information
Identifier EFO_0005055
Description
  • QRS duration is a measurement of the combined duration of the Q, R and S waves of the human heart's electric cycle
Trait category
Cardiovascular measurement
Synonyms QRS interval

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution PGS Scoring File (FTP Link)
PGS000736
(PRS_QRS)
PGP000144 |
Tadros R et al. Eur Heart J (2019)
QRS duration QRS duration 26
-
http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000736/ScoringFiles/PGS000736.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001756 PGS000736
(PRS_QRS)
PSS000903|
European Ancestry|
295 individuals
PGP000144 |
Tadros R et al. Eur Heart J (2019)
Reported Trait: QRS slope β: 0.8 (0.22) Age, SCN5A mutation
PPM001760 PGS000736
(PRS_QRS)
PSS000905|
European Ancestry|
1,185 individuals
PGP000144 |
Tadros R et al. Eur Heart J (2019)
Reported Trait: Ajmaline-induced Type I Brugada syndrome electrocardiogram OR: 1.047 [1.031, 1.063]
PPM001755 PGS000736
(PRS_QRS)
PSS000904|
European Ancestry|
1,257 individuals
PGP000144 |
Tadros R et al. Eur Heart J (2019)
Reported Trait: QRS slope β: 0.8 (0.22)
PPM001753 PGS000736
(PRS_QRS)
PSS000906|
European Ancestry|
1,193 individuals
PGP000144 |
Tadros R et al. Eur Heart J (2019)
Reported Trait: QRS slope in non SCN5A mutation carriers β: 0.93 (0.2) Correlation coefficient (r): 0.14
PPM001751 PGS000736
(PRS_QRS)
PSS000906|
European Ancestry|
1,193 individuals
PGP000144 |
Tadros R et al. Eur Heart J (2019)
Reported Trait: Baseline QRS in non SCN5A mutation carriers Correlation coefficent (r): 0.15

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000903 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.14 295 individuals European Amsterdam
PSS000904 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.12 1,257 individuals European Amsterdam
PSS000905 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.15 1,185 individuals European Amsterdam
PSS000906 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.13 1,193 individuals European Amsterdam